美国 · SEC FORM 4
Skye Bioscience, Inc.
SKYE · Nasdaq · CIK 0001516551 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
31 同一窗口内观察到的 Form 4 交易行
30 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-03-13 · 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 147,954
- 上期报告
- 117,086
- 日均成交量
- 85,208
- 回补天数
- 1.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-03-13 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 买入 (P) | Common Stock | 450,000 | USD 10.00 | USD 4,500,000 | SEC 申报 ↗ |
| 2024-01-31 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 买入 (P) | Common Stock | 5,206,074 | USD 2.31 | USD 12,026,031 | SEC 申报 ↗ |
| 2023-08-29 | DHILLON PUNIT | 买入 (P) | Common Stock | 881,000 | USD 0.02 | USD 17,620 | SEC 申报 ↗ |
| 2023-08-29 | DHILLON PUNIT | 买入 (P) | Common Stock | 881,000 | USD 0.02 | USD 17,620 | SEC 申报 ↗ |
| 2020-08-07 | HEPPELL JAMES L | 买入 (P) | Common Stock | 500,000 | USD 50,000.00 | USD 25,000,000,000 | SEC 申报 ↗ |
| 2020-08-07 | DHILLON PUNIT | 买入 (P) | Common Stock | 1,000,000 | USD 100,000.00 | USD 100,000,000,000 | SEC 申报 ↗ |
Form 4 申报证据
31 transaction lines in the latest 365-day window; 103 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Schwab Andrew J. | 卖出 (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC 申报 ↗ |
| 2026-09-23 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC 申报 ↗ |
| 2026-09-22 | Schwab Andrew J. | 卖出 (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC 申报 ↗ |
展开近期 Form 4 证据 (13 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Schwab Andrew J. | 卖出 (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC 申报 ↗ |
| 2026-09-23 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC 申报 ↗ |
| 2026-09-22 | Schwab Andrew J. | 卖出 (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC 申报 ↗ |
| 2026-09-22 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC 申报 ↗ |
| 2026-09-16 | Schwab Andrew J. | 卖出 (S) | Common Stock | 33,892 | USD 1.91 | USD 64,734 | SEC 申报 ↗ |
| 2026-09-16 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 33,892 | USD 1.91 | USD 64,734 | SEC 申报 ↗ |
| 2026-08-20 | Schwab Andrew J. | 卖出 (S) | Common Stock | 7,700 | USD 0.32 | USD 2,464 | SEC 申报 ↗ |
| 2026-08-20 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 7,700 | USD 0.32 | USD 2,464 | SEC 申报 ↗ |
| 2026-08-19 | Schwab Andrew J. | 卖出 (S) | Common Stock | 68,140 | USD 0.35 | USD 23,849 | SEC 申报 ↗ |
| 2026-08-19 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 68,140 | USD 0.35 | USD 23,849 | SEC 申报 ↗ |
| 2026-08-18 | Schwab Andrew J. | 卖出 (S) | Common Stock | 300,000 | USD 0.38 | USD 114,000 | SEC 申报 ↗ |
| 2026-08-18 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | 卖出 (S) | Common Stock | 300,000 | USD 0.38 | USD 114,000 | SEC 申报 ↗ |
| 2026-08-07 | DHILLON PUNIT | 奖励／授予 (A) | Common Stock | 1,090,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SKYE |
| CIK | 0001516551 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 103 transaction lines from 2020-08-07 to 2026-09-23 6 P purchase lines · 63 S sale lines · 34 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.